Efficacy of a sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A

  1. I. Scharrer1,
  2. H.-H. Brackmann2,
  3. Y. Sultan3,
  4. T. Abshire4,
  5. C. Gazengel5,
  6. M. Ragni6,
  7. E. Gorina7,
  8. E. Vosburgh8,
  9. E. Kellermann9

Article first published online: 5 SEP 2008

DOI: 10.1046/j.1365-2516.2000.00432.x

Issue

Haemophilia

Haemophilia

Volume 6, Issue 6, pages 614–618, November 2000

Additional Information

How to Cite

Scharrer, I., Brackmann, H.-H., Sultan, Y., Abshire, T., Gazengel, C., Ragni, M., Gorina, E., Vosburgh, E. and Kellermann, E. (2000), Efficacy of a sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A. Haemophilia, 6: 614–618. doi: 10.1046/j.1365-2516.2000.00432.x

Author Information

  1. 1

    Hemophilia Center, University of Frankfurt, Frankfurt, Germany

  2. 2

    Hemophilia Center, Institute of Experimental Hematology and Transfusion Medicine, University of Bonn, Bonn, Germany

  3. 3

    Centre de Traitement de l’Hémophilie Hôpital Cochin, Paris, France

  4. 4

    Emory University–School of Medicine, Atlanta, GA, USA

  5. 5

    Centre de Traitement de l’Hémophilie Hôpital Necker, Paris, France

  6. 6

    University of Pittsburgh–School of Medicine, Pittsburgh, PA, USA

  7. 7

    Q.F. Bayer, Barcelona, Spain

  8. 8

    Bayer Corporation, West Haven, USA

  9. 9

    Bayer Vital GmbH, Leverkusen, Germany

* Prof. Dr med. IngeScharrer Medizinische Klinik I, Hämophilie-Ambulanz., Universitätskliniken Frankfurt., Theodor-Stern-Kai 7, D-60590 Frankfurt/Main, Germany. Tel.: +49 69 6301 5051; fax: +49 69 6301 6738; e-mail: scharrer@em.uni-frankfurt.de

Publication History

  1. Issue published online: 5 SEP 2008
  2. Article first published online: 5 SEP 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (58K)

Keywords:

  • efficacy;
  • factor VIII;
  • haemostasis;
  • recombinant;
  • surgery

A sucrose-formulated recombinant FVIII (rFVIII-SF) was investigated under clinical trial conditions during surgical procedures in previously treated patients (PTPs). Fifteen PTPs with severe haemophilia A (FVIII ≤ 1%) underwent 22 surgical procedures. The procedures performed cover a spectrum from minor to major surgery. Haemostatic outcome was assessed by the investigators to be excellent in 16 procedures and good in the remaining six procedures. It is concluded that rFVIII-SF is efficacious and safe in severe haemophilia A patients undergoing minor or major surgery.

View Full Article (HTML) Get PDF (58K)